SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Cogent Biosciences Announces Initial Data From Ongoing Phase 2 Trial Of ADVSM Treatment

reuters.com · 06/10/2022 07:18
BRIEF-Cogent Biosciences Announces Initial Data From Ongoing Phase 2 Trial Of ADVSM Treatment

- Cogent Biosciences Inc COGT:

  • COGENT BIOSCIENCES ANNOUNCES POSITIVE INITIAL CLINICAL DATA FROM ONGOING PHASE 2 APEX TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

  • COGENT BIOSCIENCES INC - ALL PATIENTS TREATED WITH BEZUCLASTINIB ACHIEVED ≥50% REDUCTION IN SERUM TRYPTASE

  • COGENT - ALL BONE MARROW BIOPSY-ASSESSED PATIENTS ACHIEVED ≥50% BONE MARROW MAST CELL REDUCTION, DECREASES IN BLOOD KIT D816V VARIANT ALLELE FRACTION

  • COGENT BIOSCIENCES INC - BEZUCLASTINIB DEMONSTRATES FAVORABLE INITIAL SAFETY AND TOLERABILITY PROFILE

Source text for Eikon: ID:nGNXcgyRRW

Further company coverage: COGT


((Reuters.Briefs@thomsonreuters.com;))